Copyright © 2013 Shuqiang Zhao et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Protein fusion technology is one of themost commonly usedmethods to extend the half-life of therapeutic proteins. In this study, in order to prolong the half-life of Granulocyte colony stimulating factor (G-CSF), the domain III of human serum albumin (3DHSA) was genetically fused to the N-terminal of G-CSF. The 3DHSA-G-CSF fusion gene was cloned into pPIC
<div><p>We explore a strategy to substantially increase the half-life of recombinant proteins by gen...
In order to achieve optimal biological activity and desired pharmacokinetic profiles, a dithiocyclop...
Purpose. To improve the oral efficacy of the recombinant fusion protein containing granulocyte colon...
The purpose of the present work was to develop a novel, long-acting and potent human serum albumin/g...
<p>Protein fusion technology has emerged as one of the important strategies to increase the level of...
The purpose of the present work was to develop a novel, long-acting and potent human serum albumin/g...
The short half-life of coagulation factor IX (FIX) for haemophilia B (HB) therapy has been prolonged...
Granulocyte-Macrophage colony stimulating factor (GM-CSF) and Granulocyte colony stimulating factor ...
Background: Stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) are well-charac...
UnrestrictedIn this study, Tf-H42-G-CSF fusion protein was engineered for investigating the effects ...
Background Half-life extension strategies have gained increasing interest to improve the pharmacoki-...
A major challenge for the therapeutic use of many peptides and proteins is their short circulatory h...
Serum albumin shows slow clearance from circulation due to neonatal Fc receptor (FcRn)-mediated recy...
An expression construct harboring granulocyte colony-stimulating factor (G-CSF)-transferrin (Tf) fus...
Medical devices directly exposed to blood are commonly used to treat cardiovascular diseases. Howeve...
<div><p>We explore a strategy to substantially increase the half-life of recombinant proteins by gen...
In order to achieve optimal biological activity and desired pharmacokinetic profiles, a dithiocyclop...
Purpose. To improve the oral efficacy of the recombinant fusion protein containing granulocyte colon...
The purpose of the present work was to develop a novel, long-acting and potent human serum albumin/g...
<p>Protein fusion technology has emerged as one of the important strategies to increase the level of...
The purpose of the present work was to develop a novel, long-acting and potent human serum albumin/g...
The short half-life of coagulation factor IX (FIX) for haemophilia B (HB) therapy has been prolonged...
Granulocyte-Macrophage colony stimulating factor (GM-CSF) and Granulocyte colony stimulating factor ...
Background: Stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) are well-charac...
UnrestrictedIn this study, Tf-H42-G-CSF fusion protein was engineered for investigating the effects ...
Background Half-life extension strategies have gained increasing interest to improve the pharmacoki-...
A major challenge for the therapeutic use of many peptides and proteins is their short circulatory h...
Serum albumin shows slow clearance from circulation due to neonatal Fc receptor (FcRn)-mediated recy...
An expression construct harboring granulocyte colony-stimulating factor (G-CSF)-transferrin (Tf) fus...
Medical devices directly exposed to blood are commonly used to treat cardiovascular diseases. Howeve...
<div><p>We explore a strategy to substantially increase the half-life of recombinant proteins by gen...
In order to achieve optimal biological activity and desired pharmacokinetic profiles, a dithiocyclop...
Purpose. To improve the oral efficacy of the recombinant fusion protein containing granulocyte colon...